Hemoglobin A_1c levels and 1-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention

Abstract

Background: In this study, we investigated whether different levels of hemoglobin A_1c (HbA_1c) are associated with different short-term and 1-year mortality rates among diabetic patients undergoing percutaneous coronary intervention. Patients & methods: Clinical events including in-hospital, 1-month and 1-year mortality were compared between three groups based on HbA_1c levels of patients (I: ≤5.6%, II: 5.7–6.4%, III: ≥6.5%). Results: Among 165 diabetic individuals, patients with abnormal HbA_1c levels (≥6.5%) experienced significantly higher hospitalization days (7.65 ± 1.64 days) compared with those with normal HbA_1c (4.94 ± 0.97 days) (p < 0.0001). In-hospital mortality was significantly higher in group III (14.5%) and II (5.5%) compared with group I (0%) (p = 0.008). Conclusion: HbA_1c levels may be a reliable predictor of short-term clinical events in diabetic patients.

Summary points

• Patients with higher hemoglobin A_1c (HbA_1c) levels had more coronary arteries involved detected during angiography.

• Higher HbA_1c was intimately linked with longer hospitalization and higher in-hospital mortality rates.

• Less clear evidence was obtained regarding HbA_1c level and 1-month and 1-year mortality rates.

Keywords: :

• diabetes mellitus
• glycemic control
• hemoglobin A_1c
• mortality
• percutaneous coronary intervention

Author contributions

P Izadpanah and T Dehghanzadeh contributed to the conceptualization. The primary draft was provided by N Rahimikashkooli, A Attar and A Hosseinpour. P Izadpanah, A Attar and A Hosseinpour reviewed the draft and edited the manuscript. All the listed authors contributed substantially to the manuscript and have agreed to the final submitted version.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval (IR.SUMS.MED.REC.1398.635) and have followed the principles outlined in the Declaration of Helsinki for all human investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Data availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.